Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinas...

Full description

Bibliographic Details
Main Authors: Lorenzo Rossi, Amelia McCartney, Emanuela Risi, Luca Malorni, Laura Biganzoli, Angelo Di Leo
Format: Article
Language:English
Published: SAGE Publishing 2018-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835918815591
id doaj-3324d1073ca3434faad36eb4a26fb2a9
record_format Article
spelling doaj-3324d1073ca3434faad36eb4a26fb2a92020-11-25T03:59:48ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592018-12-011010.1177/1758835918815591Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?Lorenzo RossiAmelia McCartneyEmanuela RisiLuca MalorniLaura BiganzoliAngelo Di LeoThe current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinase 4/6 (CDK4/6). In the context of CDK4/6 inhibitors, landmark clinical trials for palbociclib (PALOMA-1, PALOMA-2, PALOMA-3), ribociclib (MONALEESA-2, MONALEESA-3, MONALEESA-7) and abemaciclib (MONARCH-1, MONARCH-2, MONARCH-3) have provided solid data regarding progression-free survival and overall response rate, justifying the introduction of this class of drugs into our therapeutic armoury. However, several clinical questions remain open. One of the most relevant issues faced in practice is that of the optimum sequencing of CDK4/6 inhibitors, particularly given the wide range of therapeutic options open to clinicians treating luminal mBC. In this brief commentary, we would like to focus on the best sequence for CDK4/6 inhibitors and their place in this growing, complex scenario.https://doi.org/10.1177/1758835918815591
collection DOAJ
language English
format Article
sources DOAJ
author Lorenzo Rossi
Amelia McCartney
Emanuela Risi
Luca Malorni
Laura Biganzoli
Angelo Di Leo
spellingShingle Lorenzo Rossi
Amelia McCartney
Emanuela Risi
Luca Malorni
Laura Biganzoli
Angelo Di Leo
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
Therapeutic Advances in Medical Oncology
author_facet Lorenzo Rossi
Amelia McCartney
Emanuela Risi
Luca Malorni
Laura Biganzoli
Angelo Di Leo
author_sort Lorenzo Rossi
title Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
title_short Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
title_full Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
title_fullStr Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
title_full_unstemmed Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
title_sort managing advanced hr-positive, her2-negative breast cancer with cdk4/6 inhibitors in post-menopausal patients: is there a best sequence?
publisher SAGE Publishing
series Therapeutic Advances in Medical Oncology
issn 1758-8359
publishDate 2018-12-01
description The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinase 4/6 (CDK4/6). In the context of CDK4/6 inhibitors, landmark clinical trials for palbociclib (PALOMA-1, PALOMA-2, PALOMA-3), ribociclib (MONALEESA-2, MONALEESA-3, MONALEESA-7) and abemaciclib (MONARCH-1, MONARCH-2, MONARCH-3) have provided solid data regarding progression-free survival and overall response rate, justifying the introduction of this class of drugs into our therapeutic armoury. However, several clinical questions remain open. One of the most relevant issues faced in practice is that of the optimum sequencing of CDK4/6 inhibitors, particularly given the wide range of therapeutic options open to clinicians treating luminal mBC. In this brief commentary, we would like to focus on the best sequence for CDK4/6 inhibitors and their place in this growing, complex scenario.
url https://doi.org/10.1177/1758835918815591
work_keys_str_mv AT lorenzorossi managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
AT ameliamccartney managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
AT emanuelarisi managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
AT lucamalorni managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
AT laurabiganzoli managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
AT angelodileo managingadvancedhrpositiveher2negativebreastcancerwithcdk46inhibitorsinpostmenopausalpatientsisthereabestsequence
_version_ 1724452829388603392

Similar Items